TaiMed Biologics to Showcase CD4-Targeted Platform Breakthroughs and High-Quality CDMO Solutions at BIO Asia-Taiwan 2026

TaiMed Biologics Inc. (4147.TWO), a globally-oriented biologics company in HIV and CD4-targeted biologics, is proud to showcase its robust "CD4-Targeted Therapeutic Roadmap" alongside its fully integrated monoclonal antibody Contract Development and Manufacturing Organization (CDMO) services at BIO Asia-Taiwan 2026 (Booth #M332), taking place July 16-19 in Taipei, Taiwan. Capitalizing on its verified track record of successful drug commercialization, TaiMed is uniquely positioned to accelerate innovative biologics toward clinical and commercial milestones for global partners.

Building on the Commercialization of Trogarzo® to Advance a CD4-Targeted Platform Centered on TMB-365

Founded in 2007, TaiMed has dedicated its core capabilities to advancing transformative therapies for HIV and other CD4-mediated diseases. The company successfully developed Trogarzo® (ibalizumab-uiyk), the first and currently the only monoclonal antibody approved by the U.S. FDA for the treatment of HIV. Trogarzo® has expanded its presence from its 2018 U.S. launch into multiple international markets, including Europe, the Middle East, North Africa, Hong Kong, Macau, and Taiwan.

At the conference, TaiMed will highlight the potential of TMB-365 as a CD4-targeted platform antibody across multiple therapeutic applications:

1. Maintenance Therapy: Advancing clinical development of TMB-365 IV infusion and the TMB-365/TMB-380 combination.
2. Emerging ADC Platforms & Future Programs: Developing innovative HIV antibody-drug conjugates (HIV ADCs), autoimmune ADCs, and other future CD4 programs designed to explore approaches to HIV reservoir elimination and future functional cure strategies.

Leveraging Commercial Expertise to Support Integrated CDMO Services

In addition to its internal pipeline, TaiMed is applying its end-to-end development and commercial manufacturing experience to support integrated CDMO services. Operating a state-of-the-art, in-house cGMP manufacturing facility in the Hsinchu Biomedical Science Park, TaiMed's dedicated technology transfer team supports efficient technology transfer of mAb programs from existing manufacturing sites to TaiMed’s facility.

1. Comprehensive End-to-End Solutions: TaiMed provides cell line and process development, formulation development, regulatory affairs, and robust analytical testing capabilities.
2. The TaiMed Advantage: The facility utilizes 100% single-use technology designed to eliminate cross-contamination risk while offering premier labor and services at highly competitive costs. With flexible production capacities spanning 50L, 200L, 500L, and 2,000L single-use bioreactors, TaiMed can accommodate programs from preclinical pilot batches to full-scale commercial manufacturing.